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Over the past 70 years our understanding of hypertension has advanced greatly. Epidemi-
ology has led to a major change in the paradigm concerning high blood pressure (BP).
Initially considered as a normal adaptation to thickened vessels, it was later recognized as
a major risk factor for cardiovascular events. Since then, the deleterious components of BP
have been reﬁned: systolic BP and pulse pressure have progressively overtaken diastolic
BP, while central pressure is becoming, for some experts, a more reliable way to mea-
sure BP than is peripheral BP. Pharmacology has led to the discovery of powerful and very
effective drugs with a good tolerance over the long term. Clinical studies have shown the
impact of lowering BP on improving patient outcomes. The beneﬁt is substantial: a reduc-
tion in systolic BP of 10—12mmHg or in diastolic BP of 5—6mmHg over 5 years resulted in a
decrease in the incidences of stroke, coronary artery disease, congestive heart failure and
cardiovascular death of 35—40%, 20—25%, 45—55% and 20—25%, respectively [1]. Finally,
tremendous efforts are still being directed at identifying new markers for cardiovascular
risk stratiﬁcation. All of these developments are summarized regularly in textbooks and
in guidelines that critically review the evidence at hand and propose the best clinical
practice in accordance with evidence-based medicine. There are, however, two areas that
have been difﬁcult to improve during this period: physicians’ compliance with practice
guidelines [2] and patients’ compliance to the prescribed treatments [3].
The paper by Nicodeme et al. [4] perfectly illustrates the complexity of improving BP
control in France. In their survey, the authors identiﬁed an approximately 40% rate of BP
control based on conventional BP measurement, close to that reported by Wang et al. [5].
While this rate is clearly not sufﬁcient, it is perhaps less disappointing than those from other
European countries [5]. More importantly, this paper reports on ‘‘clinical inertia’’, in other
words, the reluctance of physicians to modify treatment when the BP goal is not achieved.
 Poor blood pressure control in general practice: In search of explanations, Nicodème R, Albessard A, Amar J, Chamontin B, Lang T,
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Controlling BP is difﬁcult, as demonstrated clearly by
ancia and Grassi. The authors showed that even in ran-
omized trials (i.e., in very rigorous settings), only half of
he patients reached the objective in terms of systolic BP;
he proportion of patients who reached the target diastolic
P was higher [6]. The report emphasizes that, whatever the
mprovements in the management of hypertensive patients,
e will still fail to control BP in a substantial number of
ndividuals. Nevertheless, the article by Nicodeme et al. [4]
aises two important questions, the ﬁrst of which relates
o the deﬁnition of BP control. Indeed the authors, as have
any others, consider the value of 140/90mmHg by con-
entional BP measurement as the goal for the majority
f hypertensive individuals. This value has been retained
s a usual goal for treatment in most recent clinical tri-
ls. It must be put forward, however, that the response
o treatment is highly variable, while the beneﬁt is often
stimated globally and is extended to each patient. In
he Medical Research Council trial, for example, the aver-
ge BP variation after starting propranolol or bendoﬂuazide
as around —30mmHg, with an extremely wide range of
ariation, and with some patients having a greater than
0mmHg decrease and others a more than 10mmHg increase
Gueyfﬁer, personal communication). This ﬁnding clearly
hows how difﬁcult it is to extrapolate the results (here
he BP effect of a drug) from a group to an individual.
his is again perfectly illustrated by the paper by Mancia
nd Grassi [6], showing that even if the group of patients
eaches the ‘‘goal’’ on average with treatment, for exam-
le 140/90mmHg, half of the group will fail to achieve this
arget. Thus, it must be acknowledged that this threshold
or every patient is not supported by much scientiﬁc evi-
ence but is more an operational threshold proposed by
xperts to standardize routine practice. Providing the strong
rognostic value of ambulatory BP measurement [7] and the
uge variability of conventional BP measurement, another
riterion that could have been used is ‘‘normalization’’ of
mbulatory BP. The picture might have been slightly dif-
erent then. The criteria used for ‘‘controlled BP’’ should
e those that provide the best prediction of outcomes. In
his respect, ambulatory BP alone might not even be sufﬁ-
ient, since Mancia et al. have shown that the best outcomes
ere achieved in patients whose BP was ‘‘normalized’’ by all
odes of measurement, i.e. conventional, ambulatory and
elf-measurement [8]. Finally, it is generally thought that
oor BP control causes adverse outcomes. It is also conceiv-
ble that poor BP control is more a marker of hypertension
ith an intrinsic poor prognosis, for example, related to
tiffened vessels or poor socioeconomic status or renal fail-
re. In this respect, an objective of treatment based only
n BP might not be the most suitable. In terms of the impor-
ance of what should be the ultimate intermediate criteria
o constitute goals for treatment, some important research
fforts should be directed to this area, but in any case it
s now difﬁcult to limit BP control only to 140/90mmHg by
onventional BP measurement.
Another, more practical, question relates to the gap
etween clinical practice and guidelines. This is illustrated
y a recent paper showing that, in a group of 993 physi-
ians, the higher the Framingham risk score for coronary
eart disease, the lower the percentage of subjects with
orrectly targeted BP goals. This misperception may reﬂect
[
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he fact that these high-risk patients have more complicated
roﬁles, and that physicians are less prone to add antihyper-
ensive medications on top of other risk-factor treatments.
hile stringent goals are less likely to be achieved in
hese subjects, they are also those who would beneﬁt the
ost from intensive BP lowering. This failure illustrates the
ersisting need to improve the implementation of evidence-
ased guidelines in clinical practice [9]. Some clues are
roposed in the paper by Nicodeme et al. [4]. As stated
y the authors, one important step would be to simplify
nd harmonize the guidelines to avoid leaving physicians
ith sometimes conﬂicting, and perhaps even controversial,
ecommendations.
Another important point that arose from the study by
icodeme et al. [4] is the reluctance of physicians to assess
he real BP level based on their own casual measurement.
his is of course consistent with the known variability in
P and with the ‘‘white coat’’ effect. It may also rely on
he conditions of casual BP measurement that may not fulﬁl
he classical criteria of a proper measurement. In any case,
here is an urgent need to improve BP assessment and to
mplement the use of ambulatory or self-BP measurement
n general practice.
Great progress has been made in our knowledge of
ypertension, and important research efforts are still being
irected towards identifying highly sophisticated diagnostic
ools to improve risk prediction. Yet we already have sim-
le and effective markers of risk that are easily available
nd on which hypertension management should be based. It
s time to reemphasize the value of these markers, and to
obilize physicians and avoid ‘‘clinical inertia’’. Obviously,
ome patients will still have uncontrolled BP despite our
est efforts. Clinicians treating patients with refractory BP
hould follow a very rigorous management approach, involv-
ng combination treatment with synergistic drugs, titrating
he doses (especially for diuretics and spironolactone), rul-
ng out resistance factors (e.g., salt or alcohol consumption,
ncreased body weight, patient compliance with treatment),
nd searching for secondary causes. . . In these patients, a
lobal risk approach is indicated, in particular treatment
f dyslipidaemia or correction of other risk factors. Time is
concern, because the physician has to carefully evaluate
is patients and explain what could be done and why it is
mportant to do so. Patient education over the long term is
andatory to improve BP control.
Finally and fortunately, there is still room for clini-
al judgement in hypertension management. It must be
emembered that guidelines have to be interpreted for each
ndividual patient. In this respect, it is rather reassuring
hat the general health status is taken into account and
ntihypertensive treatment adapted accordingly. Long-term
reventive treatment is indeed only conceivable if there is
o other rapidly lethal disease.
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